The benzene moiety is the most prevalent
ring system in marketed
drugs, underscoring its historic popularity in drug design either
as a pharmacophore or as a scaffold that projects pharmacophoric elements.
However, introspective analyses of medicinal chemistry practices at
the beginning of the 21st century highlighted the indiscriminate deployment
of phenyl rings as an important contributor to the poor physicochemical
properties of advanced molecules, which limited their prospects of
being developed into effective drugs. This Perspective deliberates
on the design and applications of bioisosteric replacements for a
phenyl ring that have provided practical solutions to a range of developability
problems frequently encountered in lead optimization campaigns. While
the effect of phenyl ring replacements on compound properties is contextual
in nature, bioisosteric substitution can lead to enhanced potency,
solubility, and metabolic stability while reducing lipophilicity,
plasma protein binding, phospholipidosis potential, and inhibition
of cytochrome P450 enzymes and the hERG channel.